Khedr Eman M, El-Deen Hussein Bahey, El-Mokhtar Mohamed A, Mahmoud Doaa M
Department of Neurology and Psychiatry, Faculty of Medicine, Assiut University, Assiut, Egypt.
Department of Neurology and Psychiatry, Faculty of Medicine, South Valley University, Qena, Egypt.
Mult Scler Relat Disord. 2025 Aug;100:106540. doi: 10.1016/j.msard.2025.106540. Epub 2025 May 22.
Multiple sclerosis (MS) is a chronic neuroinflammatory disease with heterogeneous clinical presentations and progression rates that pose challenges to its management. Identifying prognostic biomarkers is crucial for individualized treatment approaches. Interleukin-10 (IL-10) has emerged as a key anti-inflammatory cytokine with neuroprotective effects, while Chitinase-3-like protein 1 (CHI3L1) reflects the pathogenic glial activation and neurodegeneration.
This study aimed to assess baseline serum IL-10 and CHI3L1 levels as biomarkers of disease burden and their correlation with clinical, cognitive, and quality-of-life (QoL) parameters in disease-modifying therapy (DMT)-naïve MS patients.
A cross-sectional, case-control study was conducted on 115 DMT-naïve MS patients and 15 healthy controls. Only 73 RRMS and 29 CIS confirmed MS participated in the study analysis. Serum IL-10 and CHI3L1 levels were measured using sandwich ELISA kits and were correlated with various demographic, clinical, motor, cognitive, and quality of life (QOL) parameters.
Serum levels of IL-10 and CHI3L1 were significantly higher among MS patients compared to the healthy controls (P = 0.0001 for each one) and were negatively correlated with each other (r =-0.529 and P < 0.001). Second finding IL-10 levels negatively correlated with duration of disease (r = -0.389, P < 0.001), total number of relapse (r = -0.445, P < 0.001), motor disability (EDSS), Timed 25-Foot walk test (25-FWT), and depression scores (r = -0.398, P = 0.003, r = -0.340, P = 0.002 and r = -0.288, P = 0.008 respectively). It's positively correlated with most domains of QoL. CHI3L1 correlated positively with the total number of relapses (r = 0.253, P = 0.021), and EDSS (r = 0.346, P = 0.001), while negatively correlated with vitality, social, physical function, and general health domains of QoL (P = 0.009, 0.03, 0.001, and 0.013, respectively) CONCLUSION: IL-10 serves as a potential biomarker for disease burden in MS, with protective effects on QoL, highlighting its role in the early identification of favorable disease profiles and personalized disease management.
多发性硬化症（MS）是一种慢性神经炎症性疾病，临床表现和进展速度各异，给其治疗带来挑战。识别预后生物标志物对于个体化治疗方法至关重要。白细胞介素-10（IL-10）已成为具有神经保护作用的关键抗炎细胞因子，而几丁质酶-3样蛋白1（CHI3L1）反映致病性神经胶质细胞活化和神经变性。
本研究旨在评估基线血清IL-10和CHI3L1水平作为疾病负担的生物标志物，以及它们与未接受疾病修饰治疗（DMT）的MS患者的临床、认知和生活质量（QoL）参数的相关性。
对115例未接受DMT的MS患者和15名健康对照进行了一项横断面病例对照研究。只有73例复发缓解型多发性硬化症（RRMS）和29例临床孤立综合征（CIS）确诊的MS患者参与了研究分析。使用夹心ELISA试剂盒测量血清IL-10和CHI3L1水平，并将其与各种人口统计学、临床、运动、认知和生活质量（QOL）参数相关联。
与健康对照相比，MS患者的血清IL-10和CHI3L1水平显著更高（两者P = 0.0001），且彼此呈负相关（r = -0.529，P < 0.001）。第二个发现是IL-10水平与疾病持续时间呈负相关（r = -0.389，P < 0.001）、复发总数呈负相关（r = -0.445，P < 0.001）、运动残疾（扩展残疾状态量表[EDSS]）、25英尺步行计时测试（25-FWT）和抑郁评分呈负相关（分别为r = -0.398，P = 0.003；r = -0.340，P = 0.002；r = -0.288，P = 0.008）。它与QoL的大多数领域呈正相关。CHI3L1与复发总数呈正相关（r = 0.253，P = 0.021）和EDSS呈正相关（r = 0.346，P = 0.001），而与QoL的活力（P = 0.009）、社会（P = 0.03）、身体功能（P = 0.001）和总体健康领域呈负相关（P = 0.013）。结论：IL-10可作为MS疾病负担的潜在生物标志物，对QoL具有保护作用，突出了其在早期识别有利疾病特征和个性化疾病管理中的作用。
